HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CoverGirl Brings Back ‘Blue Skies And Fresh Air,’ Niki Taylor As Turnaround Work Continues

Executive Summary

During Coty’s recent strategic update webcast, CEO Sue Nabi discussed what went wrong at CoverGirl in recent years and how the brand is reembracing its heritage to deliver “clean beauty to all.”

You may also be interested in...



Coty Extends Winning CoverGirl ‘Clean’ Strategy To Rimmel Makeup, Debuting Now

Rimmel Kind & Free follows CoverGirl Clean rollouts last year, which have helped to rejuvenate the iconic brand and endear it to a younger audience. Coty’s Consumer Beauty division recorded an 11% increase in FY 2022 second-quarter sales to $570.2m, reported, capturing global market share for the first time in five years.

Cosmetics News: Kylie Cosmetics Goes ‘Clean And Vegan’; Crowdfunded MODA MODA Shampoo; More

Shareholders and market analysts have been watching for Coty’s next Kylie Cosmetics play following the firm’s $600m deal in 2019 for a majority stake in the celeb’s highly followed makeup and skin-care business. More cosmetics news in brief.

Coty’s Prestige Biz Returns To Growth In Q3, With Green Shoots In Mass

Coty’s “booming” prestige fragrance business in the US and strong growth in China drive a 2.4% like-for-like increase in prestige beauty sales for the quarter ended on 31 March. On the mass side, Coty is actively repositioning its Rimmel and Max Factor brands as its CoverGirl revamp shows early signs of success.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel